Clinical Trial

Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to investigate the efficacy of Berberine in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. It will also learn about the safety of Berberine. The main questions it aims to answer are: Does Berberine promote the regression of IM in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking Berberine? Researchers will compare Berberine to a placebo (a look-alike substance that contains no drug) to see if uBerberine is effective in treating gastric intestinal metaplasia. Participants will: TakeBerberine or a placebo every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-12.
Trial Details
NCT Number NCT07129460
Lead Sponsor Xijing Hospital of Digestive Diseases
Conditions Gastric Intestinal Metaplasia
Enrollment 204 participants
Start Date 2025-10-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-04